Hemostatic abnormalities in children with thalassemia major and liver iron overload
Abstract
Background Thalassemia major (TM) patients are susceptible to liver dysfunction due to iron deposition. Pediatric TM patients often present with bleeding. Blood loss necessitates transfusions, leading to increased iron absorption from the gut.
Objective To study hemostatic abnormalities in children with TM and iron deposition in the liver.
Methods This cross-sectional study involved 190 non-splenectomized children with TM. Liver iron deposition was evaluated using T2* MRI. Prothrombin time (PT), activated partial thromboplastin time (aPTT), and platelet counts were assessed from blood specimens.
Results Most subjects were diagnosed with β-thalassemia and β-thalassemia/HbE. The majority of subjects were on deferiprone (DFP) treatment. Approximately 89.5% of subjects had liver iron overload. Prolongation of PT and aPTT, as well as thrombocytopenia were observed in 60%, 27.9%, and 19.5% of subjects, respectively. Prolonged aPTT and thrombocytopenia were observed three times more frequently in subjects with moderate - severe liver iron overload than in subjects with normal - mild liver iron overload (P=0.04 and 0.001, respectively).
Conclusion Most TM subjects have liver iron overload ranging from mild to severe. Prothrombin time and prolongation, as well as aPTT prolongation, and thrombocytopenia are easily found in TM children. There were significantly more moderate - severe liver iron deposition patients with aPTT prolongation and thrombocytopenia than normal – mild patients with these conditions. Hence, we suggest that pediatric TM patients undergo liver iron deposition evaluations and use iron chelators in an optimal manner, in order to limit the risk of bleeding.
References
Galanello R, Origa R. Beta-thalassemia. Orphanet J Rare Dis. 2010;5:11.
Langhi D, Ubiali EM, Marques JF, Verissimo MA, Loggetto SR, Silvinato A, et al. Guidelines on Beta-thalassemia major – regular blood transfusion therapy: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular: project guidelines: Associação Médica Brasileira – 2016. Rev Bras Hematol Hemoter. 2016;38:341–5.
Anderson ER, Shah YM. Iron hemostasis in the liver. Compr Physiol. 2013;3:315-30.
Cappellini MD, Musallam KM, Marcon A, Taher AT. Coagulopathy in beta-thalassemia: current understanding and future perspectives. Mediterr J Hematol Infect Dis. 2009;1:e2009029.
Maiti A, Chakraborti A, Chakraborty P, Mishra S. Subclinical haemorrhagic tendency exists in patients with β-thalassaemia major in early childhood. Australas Med J. 2012;5:152-5.
Naithani R, Chandra J, Narayan S, Sharma S, Singh V. Thalassemia major – on the verge of bleeding or thrombosis? Hematology. 2006;11:57-61.
Eghbali A, Taherahmadi H, Shahbazi M, Bagheri B, Ebrahimi L. Association between serum ferritin level, cardiac and liverT2-star MRI in patients with major β-thalassemia. Iran J Ped Hematol Oncol. 2014;4:17-21.
Thachil J. Relevance of clotting tests in liver disease. Postgrad Med J. 2008;84:177-81.
Caocci L, Alberti M, Burrai P, Corda R. Screening coagulation tests and clotting factors in homozygous beta-thalassemia. Acta Haematol. 1978;60:358-64.
Arruda VR. The search for the origin of factor VIII synthesis and its impact on therapeutic strategies for hemophilia A. Haematologica. 2015;100:849-50.
Capoor MN, Stonemetz JL, Baird JC, Ahmed FS, Awan A, Birkenmaier C, et al. Prothrombin time and activated partial thromboplastin time testing: a comparative effectiveness study in a million-patient sample. PLoS One. 2015;10:e0133317.
Musallam KM, Taher AT, Rachmilewitz EA. β-thalassemia intermedia: a clinical perspective. Cold Spring Harb Perspect Med. 2012;2:a013482.
Mitchell O, Feldman DM, Diakow M, Sigal SH. The pathophysiology of thrombocytopenia in chronic liver disease. Hepat Med. 2016;8:39-50.
Copyright (c) 2018 Pustika Amalia Wahidiyat, Stephen Diah Iskandar, Novie Amelia Chozie, Damayanti Sekarsari
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Authors who publish with this journal agree to the following terms:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
Accepted 2018-08-10
Published 2018-08-13
